Bioretec Ltd. has achieved a milestone with the US Food and Drug Administration (FDA) granting Breakthrough Device Designation for its RemeOs™ Spinal Interbody Cage implant. This designation affirms the product's status as a breakthrough technology in spinal surgery, marking a key moment in the field of orthopedics.

The RemeOs Spinal Interbody Cages, designed to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine, are poised to revolutionize treatment options for patients with spinal conditions.

Securing Breakthrough Device Designation is a crucial step towards launching the product in the US market. Bioretec will now assess the potential acceleration of RemeOs Spinal Cage product development and resource allocation requirements, which could impact the company's future capital needs.

Bioretec's biodegradable RemeOs™ Spinal Interbody Cage met the rigorous criteria set by the FDA for entry into the Breakthrough Device Designation program. FDA mandates that breakthrough technologies offer more effective treatment for life-threatening or irreversibly debilitating conditions, either by introducing a completely new form of treatment or by providing significant advantages over existing alternatives. These advantages may include reducing the need for hospitalization, improving patients' quality of life, and delivering long-term clinical benefits.

Under the Breakthrough Devices Program, the FDA will facilitate ongoing and prioritized interactive discussions between Bioretec and regulatory authorities regarding the commercial access of the RemeOs™ Spinal Interbody Cage implant in the US market.

Timo Lehtonen, CEO of Bioretec, expressed enthusiasm about the designation stating, "This designation gives us another validation of our expertise in creating innovative products for the unmet clinical needs in the orthopedic field." He emphasized the future prospects and market opportunities of the RemeOs™ Spinal Interbody Cage, highlighting its patented hybrid technology as a cornerstone of its success.